Effect of Once-Daily Opicapone on the Pharmacokinetics of Repaglinide
Objective: To evaluate the effect of once-daily administration of opicapone 50 mg on the pharmacokinetics (PK) of repaglinide. Background: Opicapone, a highly selective catechol-O-methyltransferase (COMT)…Impact of repeated oral administration of Opicapone on the plasma pharmacokinetics of levodopa
Objective: To examine the inhibitory effect of COMT on the plasma pharmacokinetics of levodopa resulting from repeated, once daily, oral administration of an Opicapone (OPC)…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Opicapone improves motor and non-motor wearing off symptoms in Parkinson’s disease: an observational real-world study
Objective: To assess the impact of opicapone - a third generation COMT Inhibitor - on motor and non-motor wearing off symptoms in patients suffering from…Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience
Objective: To elucidate which levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients were at higher risk for developing dyskinesia when starting opicapone (OPC) 50mg or entacapone (ENT).…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Responder analyses from the BIPARK-I double-blind experience
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the proportion of patients (ie, responders) achieving at least a 1-h reduction…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: The BIPARK-I double-blind experience
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a novel once-daily COMT inhibitor,…Relationship between Patient Global Impression of Change and other Efficacy Endpoints in Parkinson’s Disease: A post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the association of patients’ perception of Parkinson’s Disease (PD) symptoms improvement (as assessed by Patient Global Impression of Change, PGIC) could be…Effect of COMT-inhibitor in the clinical progression of Parkinson’s disease
Objective: We conducted this 2-year follow-up study to evaluate whether or not catechol-O-methyltransferase inhibitor (COMTI) has an impact on the progression or severity of Parkinson's…Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience
Objective: To explore if catechol-O-methyl-transferase inhibition (COMT-I) can prolong the efficacy of daytime intrajejunal Levodopa infusion (IJLI) in Parkinson’s disease (PD) along with a reduction…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- Next Page »